ArticleThe Journal of rheumatology2018
Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.
Article in The Journal of rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.Respiratory research · 2022Pooled it
- Defining anti-synthetase syndrome: a systematic literature review.Clinical and experimental rheumatology · 2022Pooled it
- Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Anti-Ha anti-synthetase syndrome presenting as rapidly progressive interstitial lung disease: a case report of high confidence autoantibody testing.Frontiers in immunology · 2026Article
- B cells in anti-tRNA synthetase syndrome patients show an activated, interferon-responsive signature.Frontiers in immunology · 2026Article
- Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy.Clinical reviews in allergy & immunology · 2025Review
- Idiopathic Inflammatory Myopathies-Associated Interstitial Lung Disease in Adults.Tuberculosis and respiratory diseases · 2025Article
- Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases.Clinical and experimental rheumatology · 2025Review
- Case Report: Telitacicept for interstitial lung disease associated with idiopathic inflammatory myopathies: an observational study.Frontiers in pharmacology · 2025Article
- Use of rituximab in connective tissue disease-associated interstitial lung disease: a narrative review.Frontiers in medicine · 2025Review
- Longitudinal Study of Patients with Connective Tissue Disease-Interstitial Lung Disease and Response to Mycophenolate Mofetil and Rituximab.Diagnostics (Basel, Switzerland) · 2024Article
- Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome.Arthritis research & therapy · 2024Observational
- Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease.Seminars in respiratory and critical care medicine · 2024Review
- A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.International journal of molecular sciences · 2024Review
- Connective tissue disease-associated interstitial lung disease.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Review
- Article
- A novel estrogen receptor 1: sphingomyelin phosphodiesterase acid-like 3B pathway mediates rituximab response in myositis patients.Rheumatology (Oxford, England) · 2023Article
- "Management of myositis associated interstitial lung disease".Rheumatology international · 2023Review
- A Novel Presentation of Refractory Immune Thrombocytopenia in Anti-synthetase Syndrome: A Case Report.Cureus · 2023Article
- Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease.Rheumatology international · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo assess clinical outcomes including imaging findings on computed tomography (CT), pulmonary function testing (PFT), and glucocorticoid (GC) use in patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) treated with rituximab (RTX).
methodsWe retrospectively identified all patients at 2 institutions with AS-ILD who were treated with RTX. Baseline demographics, PFT, and chest CT were assessed before and after RTX. Two radiologists independently evaluated CT using a standardized scoring system.
resultsTwenty-five subjects at the Brigham and Women's Hospital (n = 13) and University of Pittsburgh Medical Center (n = 12) were included. Antisynthetase antibodies were identified in all patients (16 Jo1, 6 PL-12, 3 PL-7). In 21 cases (84%), the principal indication for RTX use was recurrent or progressive ILD, owing to failure of other agents. Comparing pre- and post-RTX pulmonary variables at 12 months, CT score and forced vital capacity were stable or improved in 88% and 79% of subjects, respectively. Total lung capacity (%) increased from 56 ± 13 to 64 ± 13 and GC dose decreased from 18 ± 9 to 12 ± 12 mg/day. Although DLCO (%) declined slightly at 1 year, it increased from 42 ± 17 to 70 ± 20 at 3 years. The most common imaging patterns on CT were nonspecific interstitial pneumonia (NSIP; n = 13) and usual interstitial pneumonia/fibrotic NSIP (n = 5), of which 5 had concurrent elements of cryptogenic organizing pneumonia.
conclusionStability or improvement in pulmonary function or severity of ILD on CT was seen in most patients. Use of RTX was well tolerated in the majority of patients. RTX may play a therapeutic role in patients with AS-ILD, and further clinical investigation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.